Arbutus Q4 2020 Earnings Report
Key Takeaways
Arbutus Biopharma Corporation reported its fourth quarter and year-end 2020 financial results. The company's lead compound, AB-729, showed potential as a cornerstone drug in future HBV combination regimens. Several Phase 2 proof-of-concept combination clinical trials are expected to initiate this year. Arbutus expects a net cash burn between $70 to $75 million in 2021 and believes its cash runway extends through the third quarter of 2022.
AB-729 demonstrates robust declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV).
Reductions in HBsAg support a potential dosing schedule for AB-729 as infrequently as every 8 to 12 weeks.
Several AB-729 Phase 2 proof-of-concept combination clinical trials are expected to initiate this year.
AB-836, Arbutus’ proprietary oral capsid inhibitor, on track to begin a Phase 1a/1b clinical trial in the first half of 2021.
Arbutus
Arbutus
Forward Guidance
Arbutus expects a net cash burn between $70 to $75 million in 2021 and therefore the Company believes its cash runway extends through the third quarter of 2022.